A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Recruiting now · Phase 2
Conditions studied: Chronic Lymphocytic Leukemia, B-cell Malignancies
In brief
The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.
Key facts
- Study ID
- NCT07271667
- Run by
- Curis, Inc.
- People needed
- 108
- Starts
- 2026-04-23
- Expected to finish
- 2027-11-01
- Last updated by the study team
- 2026-06-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mt Sinai Comprehensive Cancer Center — Miami Beach, Florida, United States (enrolling)
- Mayo Clinic — Rochester, Minnesota, United States (enrolling)
- Summit Medical Group — Florham Park, New Jersey, United States (enrolling)
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States (enrolling)
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States (enrolling)
- Texas Oncology - Sammons Cancer Center — Dallas, Texas, United States (enrolling)
- IRCCS Ospedale San Raffaele — Milan, Italy (enrolling)
- Azienda Ospedaliero Universitaria Maggiore Della Carità — Novara, Italy (enrolling)
- Azienda Ospedale Università Padova — Padova, Italy (enrolling)
- MD Anderson Cancer Center Madrid — Madrid, Spain (enrolling)
- Hospital Universitario Fundación Jiménez Díaz - START MADRID — Madrid, Spain (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.